儿童静脉血栓栓塞症溶栓治疗的有效性与安全性:系统评价与荟萃分析
该系统评价纳入13项非随机研究,比较溶栓后抗凝与单纯抗凝在儿童静脉血栓栓塞症中的结局。溶栓可能与大出血、临床相关非大出血或未特指出血风险升高相关,风险差分别为0.09(95%CI,-0.06至0.23)、0.06(95%CI,-0.11至0.22)和0.09(95%CI,-0.04至0.23)。证据确定性极低,主要因混杂和小样本量导致的不精确性。
要点
- 纳入13项非随机研究,无随机临床试验回答这些问题。
- 溶栓可能与大出血风险差0.09(95%CI,-0.06至0.23)相关。
- 证据确定性极低,因混杂和小样本量导致的不精确性。
核心结论
- 溶栓可能与大出血、临床相关非大出血或未特指出血风险升高相关,风险差分别为0.09(95%CI,-0.06至0.23)、0.06(95%CI,-0.11至0.22)和0.09(95%CI,-0.04至0.23)。
- 在血流动力学不稳定的肺栓塞中,溶栓可能与较低死亡风险相关,但次大面积肺栓塞进展的结论不确定。
- 在深静脉血栓中,溶栓对死亡率或血栓溶解可能几乎没有影响,但可能与较低血栓后综合征风险相关。
- 在右心房血栓中,溶栓对血栓溶解可能几乎没有影响,但与大出血和死亡风险升高相关。
- 对于脑静脉窦血栓和肾静脉血栓,证据非常有限。
研究设计与样本
- 系统评价与荟萃分析,纳入13项非随机研究,无随机临床试验。
- 评估5个PICO问题,涵盖肺栓塞、肢体深静脉血栓、右心房血栓、脑静脉窦血栓和肾静脉血栓。
- 采用GRADE指南评估证据确定性。
主要发现
- 溶栓可能与大出血风险差0.09(95%CI,-0.06至0.23)相关。
- 溶栓可能与临床相关非大出血风险差0.06(95%CI,-0.11至0.22)相关。
- 溶栓可能与未特指出血风险差0.09(95%CI,-0.04至0.23)相关。
- 在血流动力学不稳定的肺栓塞中,溶栓可能与非随机研究中的较低死亡风险相关。
- 在次大面积肺栓塞中,关于肺栓塞进展的结论不确定。
关键数值与推荐
- 大出血风险差0.09(95%CI,-0.06至0.23)。
- 临床相关非大出血风险差0.06(95%CI,-0.11至0.22)。
- 未特指出血风险差0.09(95%CI,-0.04至0.23)。
- 证据确定性极低,因混杂和小样本量导致的不精确性。
临床怎么用
- 该系统评价强调为儿童静脉血栓栓塞症制定溶栓推荐存在关键挑战。
- 原文未据此给出推荐。
局限性
- 证据确定性极低,因混杂和小样本量导致的不精确性。
- 无随机临床试验回答这些问题。
- 对于脑静脉窦血栓和肾静脉血栓,证据非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted this systematic review to evaluate outcomes of thrombolysis followed by anticoagulation vs anticoagulation alone in pediatric patients with venous thromboembolism (VTE). This systematic review addresses mortality, VTE resolution, recurrence, bleeding, and organ-specific outcomes in 5 PICO (population, intervention, comparison, outcomes) questions on thrombolysis across pulmonary embolism (PE), extremity deep vein thrombosis (DVT), right atrial thrombosis (RAT), cerebral sinus venous thrombosis (CSVT), and renal vein thrombosis (RVT). Meta-analysis reported risk ratios or differences (95% confidence intervals [CIs]), and absolute effects per 1000 patients. Certainty of evidence was assessed using GRADE (Grading of recommendation, assessment, Development, and Evaluation) guidelines. Thirteen nonrandomized studies were included and no randomized clinical trials addressed these questions. Thrombolysis might be associated with a higher risk of major bleeding, clinically relevant nonmajor bleeding, or unspecified bleeding with risk differences of 0.09 (95% CI, -0.06 to 0.23), 0.06 (95% CI, -0.11 to 0.22), and 0.09 (95% CI, -0.04 to 0.23), respectively. In PE with hemodynamic compromise, thrombolysis might be associated with a lower risk of mortality but conclusions on PE progression were uncertain in submassive PE. In DVT, thrombolysis may have little to no effect on mortality or thrombus resolution but might be associated with lower risk of postthrombotic syndrome. In RAT, thrombolysis might have little to no effect on thrombus resolution but a higher risk of major bleeding and mortality. For CSVT and RVT, the evidence was very limited. These findings were based on very-low-certainty evidence because of confounding and imprecision from small sample sizes. This systematic review highlights key challenges in developing recommendations for thrombolysis in children with VTE.
引用
- Kawtharany H, Azzam M, Alkhader A, et al. Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis. Blood Adv. 2025. PMID: 40561511. doi:10.1182/bloodadvances.2025017058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。